US EditionBio-Thera signs US deal with Intas for golimumab biosimilar
Summary by Pharmaceutical-technology.com
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.2 Articles
2 Articles
All
Left
Center
Right
Accord BioPharma Strengthens Pipeline Through Exclusive U.S. Licensing Agreement with Bio-Thera for BAT2506, a Proposed Golimumab Biosimilar - Pipelinereview
BAT2506, a tumor necrosis factor-alpha (TNF-alpha) blocker, is a Phase 3 biosimilar candidate to Simponi® (golimumab) Agreement will provide Accord BioPharma with future U.S. commercialization rights to BAT2506, while Bio-Thera will maintain responsibility for product development, manufacturing, and supply RALEIGH, NC, USA I February 10, 2025 I Accord BioPharma, Inc., the U.S. specialty division of Intas Pharmaceuticals, Ltd. (“Intas Pharmaceut…
Coverage Details
Total News Sources2
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
